The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
about
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin forOptimizing the management of advanced non-small-cell lung cancer: a personal viewRole of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present eraNovel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerThe 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer managementCan microRNAs improve the management of lung cancer patients? A clinician's perspectiveExosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practiceAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesPemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Promising targets and current clinical trials in metastatic squamous cell lung cancerInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaDivergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor developmentmiR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinomaEstablishment of a first‑line second‑line treatment model for human pulmonary adenocarcinomaCost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma.Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancerA phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-sPhase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinomaIntegrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinomaNew developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules.Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach.Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerC4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinomaAdvances in adjuvant systemic therapy for non-small-cell lung cancer.The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.Pemetrexed in advanced non-small-cell lung cancer.
P2860
Q21261297-D489B40B-715E-4F48-B2AA-DDD81BA8CC07Q24656144-5347FE3D-09BA-4C60-B85F-C3737E190A95Q26774726-EDEF06F9-579F-4673-959D-28CBC5F8C004Q26827571-4BC966DD-50EE-4B57-85BE-E4BF055D5F4DQ26851443-4DA12B33-3525-4B07-AFB4-5C437BD4426EQ26999304-752CE4EE-2D26-45A4-9FFB-B59F99D2BFE4Q28066211-F6427590-BEA3-48EB-AF16-9E8A9CD3A984Q28074716-32D960F2-3A86-4EFA-A133-A52A1D84B1DAQ28081243-D24ECE18-A847-4C34-B9A7-3DF311482664Q28083663-1A0EA922-54C9-4A17-B09C-B3F292EACC62Q28303718-C34E587F-2EB1-44B1-BF34-157CFE9FAF3CQ28384678-203F76EA-9BBA-498D-A8CA-C7DFE2DEBF18Q28389722-F214B71A-8076-41A4-870C-08E34BC913CDQ28468342-31B5D3F3-D56D-46A8-BADC-B1058B6D3559Q30977332-95B0D0F8-7C2D-41A9-8079-339F116D3D8CQ30978996-B9C2D085-2222-43AC-BE09-94EC09366899Q31016138-DACB1909-4F4C-4D65-B1B8-048747E5C479Q33389316-6B4F2461-EA2E-49E5-86B8-FBE046D045D0Q33399254-029BA84D-DD20-475D-9960-69EAC38A3DFEQ33402098-92345859-6373-4727-B0C1-1A151B1D42F7Q33406653-2A9517F6-80CF-4E3B-AAFD-24E3F9A74018Q33410020-9194572F-42A8-4379-86E3-ED78C97FE5F0Q33411038-A5A009D7-106B-44C0-929C-40AB1F03576BQ33418542-A229B12B-4094-41A5-86AE-54F1703BCAD9Q33418595-B532D9D5-D59A-4BD7-9E85-EF0F437DBC98Q33422429-961B00AC-817F-4F17-8344-0A425B9B99F0Q33427832-4E86845C-04DB-4729-8770-5C420BF4C124Q33432898-1F8A1C0D-54A4-4BF6-A32D-5ED96BE270E8Q33435839-BFC47558-072A-4566-A00E-715FBCF65DBBQ33644421-7A444EFD-8943-408D-8F66-962F5B03424BQ33704088-FF00BE6E-D9E0-4C85-A088-FEDA08295A21Q33738921-149351DC-33DA-452F-8C60-67C3372E5A17Q33754141-92C08847-EBD4-4F59-89A1-F650277F32FBQ33789357-5FDE80D3-B127-4E24-A4FB-BE6CB778CDC0Q33821215-8BD59071-3EA6-421C-8281-E9975F2B35A9Q34019159-F240EFCF-35D9-4E57-8AFE-A4EDE2BDD925Q34031219-C4AA3625-7DF3-4B01-AF25-102FFE7A3F6AQ34031225-CD712E46-9684-4BFA-A5E8-26BB324BF091Q34091239-C27870CA-FE5F-4891-A614-E7C3886F3136Q34113895-D9B5B70D-68ED-4C86-AECB-1EA2A6DB4A5A
P2860
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The differential efficacy of p ...... view of two Phase III studies.
@en
The differential efficacy of p ...... view of two Phase III studies.
@nl
type
label
The differential efficacy of p ...... view of two Phase III studies.
@en
The differential efficacy of p ...... view of two Phase III studies.
@nl
prefLabel
The differential efficacy of p ...... view of two Phase III studies.
@en
The differential efficacy of p ...... view of two Phase III studies.
@nl
P2093
P1433
P1476
The differential efficacy of p ...... view of two Phase III studies.
@en
P2093
Frances A Shepherd
Giorgio Scagliotti
Johannes Blatter
Katherine Sugarman
Lorinda Simms
Nasser Hanna
Patrick Peterson
P304
P356
10.1634/THEONCOLOGIST.2008-0232
P577
2009-02-16T00:00:00Z